newsfilter
← Latest News
PR Newswire·

Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma

  • Swedish Orphan Biovitrum AB (Sobi) & Innate Pharma SA have entered a strategic partnership to initiate the TELLOMAK-3 Phase 3 study for lacutamab in cutaneous T-cell lymphoma (CTCL).
  • The TELLOMAK-3 trial will support a planned accelerated approval filing for Sézary syndrome & subsequent applications for full approval in Sézary syndrome & mycosis fungoides.
  • Sobi will receive exclusive global commercialization rights upon potential accelerated approval & may assume full global development rights following positive Phase 3 results.
  • Sobi will pay Innate Pharma USD 75 million upon closing, subject to regulatory & anti-trust clearances.
  • Innate Pharma is eligible for up to USD 40 million in near-term development milestones, up to USD 465 million for development rights options & future regulatory/commercial milestones, & tiered double-digit royalties on net sales.
  • Lacutamab is a first-in-class anti-KIR3DL2 antibody currently holding Fast Track, PRIME, Orphan Drug, & Breakthrough Therapy designations for CTCL indications.
  • The TELLOMAK-3 study is an open-label, multicenter, randomized trial focusing on progression-free survival (PFS) as the primary endpoint for patients who have failed prior systemic therapies.